150 related articles for article (PubMed ID: 35656509)
1. Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer-Prevalence and Current Clinical Practice.
Patel PH; Tunariu N; Levine DS; de Bono JS; Eeles RA; Khoo V; Murray J; Parker CC; Pathmanathan A; Reid A; van As N; Tree AC
Front Oncol; 2022; 12():862995. PubMed ID: 35656509
[TBL] [Abstract][Full Text] [Related]
2. Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer.
Massaro M; Facondo G; Vullo G; Aschelter AM; Rossi A; De Sanctis V; Marchetti P; Osti MF; Valeriani M
Front Oncol; 2021; 11():695136. PubMed ID: 34631527
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience.
Valeriani M; Marinelli L; Macrini S; Reverberi C; Aschelter AM; De Sanctis V; Marchetti P; Tronnolone L; Osti MF
Radiat Oncol; 2019 Nov; 14(1):205. PubMed ID: 31727093
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy.
Ingrosso G; Detti B; Fodor A; Caini S; Borghesi S; Triggiani L; Trippa F; Russo D; Bruni A; Francolini G; Lancia A; Marinelli L; Di Muzio N; Livi L; Magrini SM; Maranzano E; Musio D; Aristei C; Valeriani M
Clin Transl Oncol; 2021 Aug; 23(8):1577-1584. PubMed ID: 33495981
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide.
La Vecchia M; Fazio I; Borsellino N; Lo Casto A; Galanti D
Tumori; 2023 Aug; 109(4):413-417. PubMed ID: 36358013
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy at oligoprogression for metastatic castration-resistant prostate cancer patients: a multi-institutional analysis.
Valeriani M; Detti B; Fodor A; Caini S; Borghesi S; Trippa F; Triggiani L; Bruni A; Russo D; Saldi S; Di Staso M; Francolini G; Lancia A; Marinelli L; Di Muzio N; Aristei C; Livi L; Magrini SM; Ingrosso G
Radiol Med; 2022 Jan; 127(1):108-116. PubMed ID: 34748151
[TBL] [Abstract][Full Text] [Related]
8. Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer.
Deek MP; Taparra K; Phillips R; Velho PI; Gao RW; Deville C; Song DY; Greco S; Carducci M; Eisenberger M; DeWeese TL; Denmeade S; Pienta K; Paller CJ; Antonarakis ES; Olivier KR; Park SS; Tran PT; Stish BJ
Eur Urol Oncol; 2021 Jun; 4(3):447-455. PubMed ID: 32536574
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic radiotherapy to oligoprogressive lesions detected with
Onal C; Ozyigit G; Oymak E; Guler OC; Tilki B; Hurmuz P; Akyol F
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3683-3692. PubMed ID: 33693965
[TBL] [Abstract][Full Text] [Related]
10. Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection.
Franzese C; Perrino M; Marzo MA; Badalamenti M; Baldaccini D; D'Agostino G; Marini B; De Vincenzo F; Zucali PA; Scorsetti M
Clin Exp Metastasis; 2022 Jun; 39(3):449-457. PubMed ID: 35190933
[TBL] [Abstract][Full Text] [Related]
11. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
Tsai CJ; Yang JT; Shaverdian N; Patel J; Shepherd AF; Eng J; Guttmann D; Yeh R; Gelblum DY; Namakydoust A; Preeshagul I; Modi S; Seidman A; Traina T; Drullinsky P; Flynn J; Zhang Z; Rimner A; Gillespie EF; Gomez DR; Lee NY; Berger M; Robson ME; Reis-Filho JS; Riaz N; Rudin CM; Powell SN;
Lancet; 2024 Jan; 403(10422):171-182. PubMed ID: 38104577
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer.
Kawai T; Taguchi S; Nozaki K; Kimura N; Oshina T; Iwaki T; Matsui H; Niimi A; Kamei J; Akiyama Y; Yamada Y; Sato Y; Yamada D; Kaneko T; Sawayanagi S; Nakayama H; Minamimoto R; Yamashita H; Miyazaki H; Fujimura T; Nakagawa T; Kume H
Prostate Int; 2023 Dec; 11(4):239-246. PubMed ID: 38196558
[TBL] [Abstract][Full Text] [Related]
13. Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer.
Berghen C; Joniau S; Ost P; Poels K; Everaerts W; Decaestecker K; Haustermans K; Devos G; De Meerleer G
Eur Urol Oncol; 2021 Apr; 4(2):305-309. PubMed ID: 31558422
[TBL] [Abstract][Full Text] [Related]
14. Is stereotactic body radiotherapy an effective treatment in metastatic lung cancer with oligoprogressive disease?
Aquilano M; Loi M; Visani L; Livi L; Nuyttens JJ
Acta Oncol; 2023 Mar; 62(3):298-304. PubMed ID: 36905644
[TBL] [Abstract][Full Text] [Related]
15. The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer.
Le Guevelou J; Cuccia F; Flippot R; Ferrera G; Terlizzi M; Zilli T; De Crevoisier R; Hannoun-Levi JM; Supiot S; Sargos P; Pasquier D
Prostate Cancer Prostatic Dis; 2024 Jun; ():. PubMed ID: 38898265
[TBL] [Abstract][Full Text] [Related]
16. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
17. Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer.
Weykamp F; König L; Seidensaal K; Forster T; Hoegen P; Akbaba S; Mende S; Welte SE; Deutsch TM; Schneeweiss A; Debus J; Hörner-Rieber J
Front Oncol; 2020; 10():987. PubMed ID: 32676455
[No Abstract] [Full Text] [Related]
18. Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.
Xuzhang W; Huang H; Yu Y; Shen L; Li Z; Lu S
Ther Adv Med Oncol; 2023; 15():17588359231156387. PubMed ID: 36895853
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiotherapy for oligoprogression with or without switch of systemic therapy.
Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; Tanadini-Lang S; Mayinger M; Guckenberger M; Andratschke N
Clin Transl Radiat Oncol; 2024 Mar; 45():100748. PubMed ID: 38433950
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic Radiotherapy for Lesions Detected via
Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y
Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
